{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:12:04Z","timestamp":1790212324082,"version":"4.1.0"},"reference-count":110,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22212MFDS261"],"award-info":[{"award-number":["22212MFDS261"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles. Government agencies, cancer hospitals, and academic societies with accumulated experiences led investigator-initiated precision oncology clinical trials (IIPOCTs), which later guided sponsor-initiated precision oncology clinical trials (SIPOCTs). Most SIPOCTs were international studies with basket design. IIPOCTs primarily used the central laboratory for biomarker screening, but SIPOCTs used both central and local laboratories. Most of the studies adapted next-generation sequencing and\/or immunohistochemistry for biomarker screening. Fifteen studies included an independent central review committee for outcome investigation. Efficacy assessments predominantly featured objective response rate as the primary endpoint, with varying results. Nine eligible studies contributed to the United States Food and Drug Administration\u2019s marketing authorization. Safety monitoring was rigorous, but reporting formats lacked uniformity. Health-related quality of life and patient-reported outcomes were described in some protocols but rarely reported. Our results reveal that precision oncology trials with adaptive design rapidly and efficiently evaluate anticancer drugs\u2019 efficacy and safety, particularly in specified biomarker-driven cohorts. The evolution from IIPOCT to SIPOCT has facilitated fast regulatory approval, providing valuable insights into the precision oncology landscape.<\/jats:p>","DOI":"10.4143\/crt.2024.128","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:21:20Z","timestamp":1715044880000},"page":"991-1013","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design"],"prefix":"10.4143","volume":"56","author":[{"given":"Hyerim","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Yeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jung","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungJin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-sung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8274.cd-10-0010"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.12.003"},{"key":"ref3","volume-title":"Adaptive design clinical trials for drugs and biologics guidance for industry [Internet]","year":"2019"},{"key":"ref4","volume-title":"Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry [Internet]","year":"2022"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"ref7","first-page":"3546","volume-title":"Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: arms A and B of the AcSe-ESMART trial","author":"Bautista","year":"2021"},{"key":"ref8","first-page":"53","volume-title":"Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed\/refractory solid tumours: arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium","author":"Pasqualini","year":"2021"},{"key":"ref9","first-page":"268","volume-title":"First-in-child phase I\/II study of the dual mTORC1\/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSeESMART trial","author":"Morscher","year":"2021"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.016"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(18)30116-4"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.011"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx774"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.10.015"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.029"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.027"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.041"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002973"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.01.001"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2209"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30475-7"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-3473"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.88"},{"key":"ref24","first-page":"36","volume-title":"Lung-MAP: framework, overview, and design principles","author":"Ferrarotto","year":"2015"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00165"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00424"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01648"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00762"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz291"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02630"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00372"},{"key":"ref32","first-page":"e2200505","volume-title":"Olaparib in patients with metastatic prostate vancer with BRCA1\/2 mutation: results from the TAPUR study","author":"Yang","year":"2023"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00191"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00306"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02923"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00037"},{"key":"ref39","first-page":"10","volume-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study","author":"Mangat","year":"2018"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01933-w"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.008"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0450"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00336-3"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30904-5"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.018"},{"key":"ref46","first-page":"33","volume-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","author":"Strickler","year":"2023"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00605-7"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2103695"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac080"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00418"},{"key":"ref51","first-page":"997","volume-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","author":"Doz","year":"2022"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1172\/jci144847"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30856-3"},{"key":"ref54","first-page":"731","volume-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","author":"Drilon","year":"2018"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33195"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30671-0"},{"key":"ref57","first-page":"6428","volume-title":"Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial","author":"Clark","year":"2021"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650"},{"key":"ref60","first-page":"1059","volume-title":"MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial","author":"Chien","year":"2020"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1513749"},{"key":"ref62","first-page":"11","volume-title":"Adaptive randomization of neratinib in early breast cancer","author":"Park","year":"2016"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2535"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33048"},{"key":"ref65","first-page":"331","volume-title":"Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma","author":"Nakauma-Gonzalez","year":"2022"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3752"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1600-x"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.025"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/nature25475"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0966"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36399-y"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00188-6"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01436"},{"key":"ref74","first-page":"3705","volume-title":"Inhibition of WEE1 is effective in TP53- and RAS-mutant netastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","author":"Seligmann","year":"2021"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01999"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(17)30394-1"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2481-8"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv394"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00120-0"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00247-3"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00541-1"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100551"},{"key":"ref84","first-page":"4160","volume-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","author":"Subbiah","year":"2021"},{"key":"ref85","first-page":"825","volume-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","author":"Wirth","year":"2020"},{"key":"ref86","first-page":"813","volume-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","author":"Drilon","year":"2020"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013658"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00578-7"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30321-1"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.6785"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.51.1766"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100072"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03025"},{"key":"ref96","first-page":"261","volume-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","author":"Drilon","year":"2020"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30691-6"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5029"},{"key":"ref99","first-page":"733","volume-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS (G12C) mutation: a randomised, open-label, phase 3 trial","author":"de Langen","year":"2023"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.9990"},{"key":"ref101","first-page":"726","volume-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","author":"Hyman","year":"2015"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-023-00500-w"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1266286"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy008"},{"key":"ref105","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) [Internet]","year":"2020"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.09.032"},{"key":"ref107","first-page":"dju244","volume-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","author":"Basch","year":"2014"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00269.x"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2004.09.003"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5579-3"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T19:44:13Z","timestamp":1728848653000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.128","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"2024-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-07","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}